Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials

Daniela F. Ward Grados; Hamed Ahmadi; Thomas S. Griffith; Christopher A. Warlick

doi:10.1080/08820139.2022.2118606

Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials

Daniela F. Ward Grados, Hamed Ahmadi, Thomas S. Griffith, Christopher A. Warlick

Urology

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line therapy for non-muscle invasive disease. However, the remarkable results obtained with checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled the quest to optimize these and other forms of immunotherapy for both non-muscle invasive as well as advanced bladder cancer. In this review we summarize the current state of the rapidly evolving field of immunotherapy in bladder cancer highlighting novel approaches and ongoing trials in this exciting area of research.

Original language	English (US)
Pages (from-to)	2226-2251
Number of pages	26
Journal	Immunological Investigations
Volume	51
Issue number	8
DOIs	https://doi.org/10.1080/08820139.2022.2118606
State	Published - 2022

Bibliographical note

Funding Information:
The author(s) reported there is no funding associated with the work featured in this article.

Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

Keywords

BCG
bladder cancer
checkpoint inhibitors
immune targeted therapy
immunotherapy

PubMed: MeSH publication types

Review
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1080/08820139.2022.2118606

OpenUrl availability

Full text

Cite this

@article{cfddf787c0fc4b819f58537cada18c06,

title = "Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials",

abstract = "For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line therapy for non-muscle invasive disease. However, the remarkable results obtained with checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled the quest to optimize these and other forms of immunotherapy for both non-muscle invasive as well as advanced bladder cancer. In this review we summarize the current state of the rapidly evolving field of immunotherapy in bladder cancer highlighting novel approaches and ongoing trials in this exciting area of research.",

keywords = "BCG, bladder cancer, checkpoint inhibitors, immune targeted therapy, immunotherapy",

author = "{Ward Grados}, {Daniela F.} and Hamed Ahmadi and Griffith, {Thomas S.} and Warlick, {Christopher A.}",

note = "Funding Information: The author(s) reported there is no funding associated with the work featured in this article. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/08820139.2022.2118606",

language = "English (US)",

volume = "51",

pages = "2226--2251",

journal = "Immunological Investigations",

issn = "0882-0139",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Immunotherapy for Bladder Cancer

T2 - Latest Advances and Ongoing Clinical Trials

AU - Ward Grados, Daniela F.

AU - Ahmadi, Hamed

AU - Griffith, Thomas S.

AU - Warlick, Christopher A.

N1 - Funding Information: The author(s) reported there is no funding associated with the work featured in this article. Publisher Copyright: © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2022

Y1 - 2022

N2 - For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line therapy for non-muscle invasive disease. However, the remarkable results obtained with checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled the quest to optimize these and other forms of immunotherapy for both non-muscle invasive as well as advanced bladder cancer. In this review we summarize the current state of the rapidly evolving field of immunotherapy in bladder cancer highlighting novel approaches and ongoing trials in this exciting area of research.

AB - For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line therapy for non-muscle invasive disease. However, the remarkable results obtained with checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled the quest to optimize these and other forms of immunotherapy for both non-muscle invasive as well as advanced bladder cancer. In this review we summarize the current state of the rapidly evolving field of immunotherapy in bladder cancer highlighting novel approaches and ongoing trials in this exciting area of research.

KW - BCG

KW - bladder cancer

KW - checkpoint inhibitors

KW - immune targeted therapy

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85138227482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138227482&partnerID=8YFLogxK

U2 - 10.1080/08820139.2022.2118606

DO - 10.1080/08820139.2022.2118606

M3 - Review article

C2 - 36083246

AN - SCOPUS:85138227482

SN - 0882-0139

VL - 51

SP - 2226

EP - 2251

JO - Immunological Investigations

JF - Immunological Investigations

IS - 8

ER -

Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this